

**Treatment-Experienced Patients
All Patients**

TABLE 131: SVR GENOTYPE 3 TREATMENT-EXPERIENCED: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	PR48	1.52 (1.35 to 1.69)	28.39 (19.53 to 37.00)
DCV12 + SOF12		1.72 (1.44 to 1.86)	39.32 (24.20 to 45.32)
SOF12 + PR12		1.53 (1.09 to 1.77)	28.72 (4.64 to 41.13)
DCV12 + SOF12	SOF24 + RBV24	1.13 (0.93 to 1.28)	10.59 (–6.18 to 21.14)
SOF12 + PR12		1.00 (0.70 to 1.20)	0.15 (–25.27 to 15.48)
SOF12 + PR12	DCV12 + SOF12	0.89 (0.63 to 1.11)	–10.10 (–34.80 to 8.78)
Random effect model	Residual deviance	10.56 vs. 10 data points	

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
	Deviance information criteria		66.132
Fixed effect model	Residual deviance	11.32 vs. 10 data points	
	Deviance information criteria		66.119

Cri = credible interval; DCV = daclatasvir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.
 Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.